Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 6Rectal Neoplasms 4Colorectal Neoplasms 4Sarcoma 2Prostatic Neoplasms 2Osteosarcoma 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Astrocytoma 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Breast Carcinoma In Situ 1Brain Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 92Nivolumab 56Ipilimumab 55Cyclophosphamide 52Vemurafenib 28fludarabine 27aldesleukin 25Interleukin-2 25fludarabine phosphate 21trametinib 20dabrafenib 17Temozolomide 14Biopsy 14Cisplatin 13spartalizumab 12atezolizumab 12Carboplatin 11cobimetinib 10Paclitaxel 10Introns 10CTLA-4 Antigen 10poly ICLC 9binimetinib 9Specimen Handling 9Radiotherapy 9Radiosurgery 9MART-1 Antigen 9tremelimumab 8incomplete Freund's adjuvant 8Radiation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Melanoma × Neoadjuvant Therapy × Clear all
NCT00667901 2009-12-11

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Rutgers, The State University of New Jersey

Phase 1 Terminated
15 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡